Literature DB >> 19802006

HEY1 Leu94Met gene polymorphism dramatically modifies its biological functions.

M A Villaronga1, D N Lavery, C L Bevan, S Llanos, B Belandia.   

Abstract

The hairy/enhancer-of-split related with YRPW motif 1 (HEY1) is a member of the basic-helix-loop-helix-Orange (bHLH-O) family of transcriptional repressors that mediate Notch signaling. Several cancer-related pathways also regulate HEY1 expression, and HEY1 itself acts as an indirect positive regulator of the p53 tumor suppressor protein and a negative regulator of androgen receptor activity. In this study we show how a naturally occurring non-synonymous polymorphism at codon 94 of HEY1, which results in a substitution of leucine by methionine (Leu94Met), converts HEY1 from an androgen receptor corepressor to an androgen receptor co-activator without affecting its intrinsic transcriptional repressive domains. The polymorphism Leu94Met also abolishes HEY1-mediated activation of p53 and suppresses the ability of HEY1 to induce p53-dependent cell-cycle arrest and aberrant cell differentiation in human osteosarcoma U2OS cells. Moreover, expression of HEY1, but not of the variant Leu94Met, confers sensitivity to p53-activating chemotherapeutic drugs on U2OS cells. In addition, we have identified motifs in HEY1 that are critical for the regulation of its subcellular localization and analysed how mutations in those motifs affect both HEY1 and HEY1-Leu94Met functions. These findings suggest that the polymorphism Leu94Met in HEY1 radically alters its biological activities and may affect oncogenic processes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19802006      PMCID: PMC3381846          DOI: 10.1038/onc.2009.309

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  36 in total

1.  Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism.

Authors:  Catia Giovannini; Laura Gramantieri; Pasquale Chieco; Manuela Minguzzi; Federica Lago; Simona Pianetti; Eric Ramazzotti; Kenneth B Marcu; Luigi Bolondi
Journal:  J Hepatol       Date:  2009-03-10       Impact factor: 25.083

Review 2.  Transcriptional control of skeletogenesis.

Authors:  Gerard Karsenty
Journal:  Annu Rev Genomics Hum Genet       Date:  2008       Impact factor: 8.929

3.  Down-regulation of Jagged-1 induces cell growth inhibition and S phase arrest in prostate cancer cells.

Authors:  Yuxiang Zhang; Zhiwei Wang; Fakhara Ahmed; Sanjeev Banerjee; Yiwei Li; Fazlul H Sarkar
Journal:  Int J Cancer       Date:  2006-11-01       Impact factor: 7.396

Review 4.  Germ line polymorphism in metastatic progression.

Authors:  Kent W Hunter; Nigel P Crawford
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

Review 5.  Notch signaling: a potential therapeutic target in prostate cancer.

Authors:  M A Villaronga; C L Bevan; B Belandia
Journal:  Curr Cancer Drug Targets       Date:  2008-11       Impact factor: 3.428

Review 6.  Polymorphisms in the p53 pathway.

Authors:  E C Pietsch; O Humbey; M E Murphy
Journal:  Oncogene       Date:  2006-03-13       Impact factor: 9.867

Review 7.  Targeting p53 for enhanced radio- and chemo-sensitivity.

Authors:  Chao Lu; Wafik S El-Deiry
Journal:  Apoptosis       Date:  2009-04       Impact factor: 4.677

8.  A role for the transcription factor HEY1 in glioblastoma.

Authors:  Esther Hulleman; Micaela Quarto; Richard Vernell; Giacomo Masserdotti; Elena Colli; Johan M Kros; Daniel Levi; Paolo Gaetani; Patrizia Tunici; Gaetano Finocchiaro; Riccardo Rodriguez Y Baena; Maria Capra; Kristian Helin
Journal:  J Cell Mol Med       Date:  2008-03-17       Impact factor: 5.310

9.  Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation.

Authors:  M Tanaka; T Setoguchi; M Hirotsu; H Gao; H Sasaki; Y Matsunoshita; S Komiya
Journal:  Br J Cancer       Date:  2009-05-19       Impact factor: 7.640

10.  Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling.

Authors:  Christopher J Lengner; Heather A Steinman; James Gagnon; Thomas W Smith; Janet E Henderson; Barbara E Kream; Gary S Stein; Jane B Lian; Stephen N Jones
Journal:  J Cell Biol       Date:  2006-03-13       Impact factor: 10.539

View more
  11 in total

Review 1.  Specific changes in the expression of imprinted genes in prostate cancer--implications for cancer progression and epigenetic regulation.

Authors:  Teodora Ribarska; Klaus-Marius Bastian; Annemarie Koch; Wolfgang A Schulz
Journal:  Asian J Androl       Date:  2012-02-27       Impact factor: 3.285

2.  The transcription factor CREBZF is a novel positive regulator of p53.

Authors:  Irene López-Mateo; M Ángeles Villaronga; Susana Llanos; Borja Belandia
Journal:  Cell Cycle       Date:  2012-09-14       Impact factor: 4.534

3.  Repression of androgen receptor activity by HEYL, a third member of the Hairy/Enhancer-of-split-related family of Notch effectors.

Authors:  Derek N Lavery; M Angeles Villaronga; Marjorie M Walker; Anup Patel; Borja Belandia; Charlotte L Bevan
Journal:  J Biol Chem       Date:  2011-03-17       Impact factor: 5.157

Review 4.  Pharmacogenomics and cancer stem cells: a changing landscape?

Authors:  Francesco Crea; Maria Ana Duhagon; William L Farrar; Romano Danesi
Journal:  Trends Pharmacol Sci       Date:  2011-04-27       Impact factor: 14.819

5.  Notch-induced transcription factors are predictive of survival and 5-fluorouracil response in colorectal cancer patients.

Authors:  P A Candy; M R Phillips; A D Redfern; S M Colley; J A Davidson; L M Stuart; B A Wood; N Zeps; P J Leedman
Journal:  Br J Cancer       Date:  2013-07-30       Impact factor: 7.640

6.  Androgen receptor signalling in prostate cancer: the functional consequences of acetylation.

Authors:  Derek N Lavery; Charlotte L Bevan
Journal:  J Biomed Biotechnol       Date:  2010-12-28

7.  CD248 facilitates tumor growth via its cytoplasmic domain.

Authors:  Margarida Maia; Astrid DeVriese; Tom Janssens; Michaël Moons; Rik J Lories; Jan Tavernier; Edward M Conway
Journal:  BMC Cancer       Date:  2011-05-08       Impact factor: 4.430

8.  Hairy/enhancer-of-split related with YRPW motif protein 1 promotes osteosarcoma metastasis via matrix metallopeptidase 9 expression.

Authors:  A Tsuru; T Setoguchi; Y Matsunoshita; H Nagao-Kitamoto; S Nagano; M Yokouchi; S Maeda; Y Ishidou; T Yamamoto; S Komiya
Journal:  Br J Cancer       Date:  2015-03-31       Impact factor: 7.640

9.  CHK1 expression in Gastric Cancer is modulated by p53 and RB1/E2F1: implications in chemo/radiotherapy response.

Authors:  J Bargiela-Iparraguirre; L Prado-Marchal; M Fernandez-Fuente; A Gutierrez-González; J Moreno-Rubio; M Muñoz-Fernandez; M Sereno; R Sanchez-Prieto; R Perona; I Sanchez-Perez
Journal:  Sci Rep       Date:  2016-02-12       Impact factor: 4.379

10.  HEY1 functions are regulated by its phosphorylation at Ser-68.

Authors:  Irene López-Mateo; Amaia Arruabarrena-Aristorena; Cristina Artaza-Irigaray; Juan A López; Enrique Calvo; Borja Belandia
Journal:  Biosci Rep       Date:  2016-06-03       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.